Inlyta (axitinib) / Pfizer  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inlyta (axitinib) / Pfizer
KEYNOTE 426, NCT02853331 / 2016-000588-17: Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Checkmark Long-term follow-up data from KEYNOTE-426 trial in combination with axitinib for RCC at ASCO 2021
Jun 2021 - Jun 2021: Long-term follow-up data from KEYNOTE-426 trial in combination with axitinib for RCC at ASCO 2021
Checkmark Long term follow-up data from KEYNOTE-426 trial in combination with Inlyta for RCC
May 2020 - May 2020: Long term follow-up data from KEYNOTE-426 trial in combination with Inlyta for RCC
Checkmark KEYNOTE-426 trial in combination with Inlyta in 1L advanced RCC at ASCO-GU 2019
More
Active, not recruiting
3
861
NA
Pembrolizumab, MK-3475, KEYTRUDA®, Axitinib, INLYTA®, Sunitinib, SUTENT®
Merck Sharp & Dohme LLC
Renal Cell Carcinoma
10/18
12/25
AxiPRO, NCT04764487: A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

Recruiting
3
178
Europe
KidneyPRO, web-application, standard follow-up
Weprom, Pfizer, FLGXPL
Renal Cell Carcinoma Metastatic
06/23
06/25
RENOTORCH, NCT04394975: Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Active, not recruiting
3
421
RoW
Biological : Toripalimab Drug: Axitinib, sunitinib
Shanghai Junshi Bioscience Co., Ltd.
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
06/23
06/23
JAVELIN Renal 101, NCT02684006 / 2015-002429-20: A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer

Checkmark Data from JAVELIN Renal 101 trial in combination with axitinib for IL RCC at ESMO 2019
Sep 2019 - Oct 2019: Data from JAVELIN Renal 101 trial in combination with axitinib for IL RCC at ESMO 2019
Checkmark JAVELIN Renal 101 trial in 1L mRCC
Feb 2019 - Feb 2019: JAVELIN Renal 101 trial in 1L mRCC
Checkmark Data presentation from JAVELIN Renal 101 trial in combination with Inlyta for 1L RCC at ESMO 2018
More
Completed
3
886
Europe, Canada, Japan, US, RoW
Avelumab (MSB0010718C), Axitinib (AG-013736), Inlyta, Sunitinib, Sutent
Pfizer
Renal Cell Cancer
08/23
06/24
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
CARE1, NCT06364631: Pragmatic Clinical Trial

Recruiting
3
1250
Europe
Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA
Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
05/32
05/32
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting
3
62
Europe, Canada, Japan, US, RoW
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Pfizer
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
09/26
09/26
NCT01744249 / 2011-001550-29: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Active, not recruiting
2/3
255
Europe
Axitinib, Sandostatin LAR, Placebo
Grupo Espanol de Tumores Neuroendocrinos, Pfizer
Neuroendocrine Tumors, Advanced Cancer
08/21
10/21
FRUSICA-2, NCT05522231: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma

Recruiting
2/3
264
RoW
fruquintinib+sintilimab, HMPL-013 + IBI308, axitinib / everolimus, fruquintinib, HMPL-013
Hutchison Medipharma Limited
Advanced Renal Cell Carcinoma
11/24
03/25
NCT06020352: The Efficacy and Safety of KN046 Combined With Axitinib

Recruiting
2/3
20
RoW
KN046 plus Axitinib, surgical resection and selective adjuvant therapy with KN046
Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
07/25
07/25

Download Options